Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern
Recommend:
0

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago DARDEN RESTAURANTS : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
<1m ago SOUH AMER0 : South American Properties, Inc. -- 2013 Annual Shareholder Meeting Held; New Name Change and Company Direction Announced
2m ago TATA POWER : Mumbai faces massive outage as Tata Power unit trips
2m ago K ELECTRIC : 2 killed, 2 injured in violence
2m ago MARRIOTT : Security Analyst Meeting Webcast: September 8
2m ago NPS NATIONAL PARK SERVICE : Keweenaw National Historical Park — This month’s National Park Getaway
2m ago WASTE MANAGEMENT : Exclusive: Deutsche Asset & Wealth Management opens Dallas office in regional shift
3m ago GLUSKIN SHEFF + ASSOCIATES : Announces Fourth Quarter and Year End Fiscal 2014 Results and Conference Call
4m ago ELY GOLD & MINERALS : and Solitario Completes Environmental Assessment Process on its Mt. Hamilton Gold Project, Nevada
4m ago GOVERNMENT OF BRITISH COLUMBIA : BC Coroners Service Confirms Identity in Rock-Climbing Incident
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Espirito Santo debt attracts potential buyers at 2 percent of face value
CORRECT : Dixons Carphone Confirms Long Term Deal With Vodafone
EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
TMM REAL ESTATE DEVELOPMENT : Sonyachna Brama residential complex construction status update
COMPUWARE : to be Acquired by Thoma Bravo
Most Read News
1d ago FORMFACTOR : Raises Third Quarter Guidance Range
1d ago STUART OLSON : announces sale of Broda Construction
13h ago MANCHESTER UNITED : Van Gaal Speaks on Di Maria Injury
1d ago MEDICINOVA : to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
1d ago EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Most recommended articles
1d agoDJZambia Copper Miners Say Crippled by Unpaid $600 Million Tax Refund-Mines Body
4d ago S&P 500 edges up to set new record; best month since Feb
2m ago WASTE MANAGEMENT : Exclusive: Deutsche Asset & Wealth Management opens Dallas office in regional shift
5m ago Halliburton to settle U.S. Gulf spill claims for $1.1 billion
7m agoDJAnother American Doctor Infected With Ebola
Dynamic quotes  
ON
| OFF